中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

62 records (took 0.028 seconds)

    클로피도그렐 베실레이트를 포함하는 약학 조성물 및 그의제조방법
    33.
    发明授权
    클로피도그렐 베실레이트를 포함하는 약학 조성물 및 그의제조방법 失效
    包含焦磷酸乙酯的药物组合物及其制备方法

    公开(公告)号：KR100805675B1

    公开(公告)日：2008-02-21

    申请号：KR1020070022408

    申请日：2007-03-07

    Applicant: 한림제약(주)

    Inventor： 김재신 ,  류종현 ,  이근혁 ,  전세화 ,  김진선

    IPC: A61K31/4365 ,  A61K9/14

    CPC classification number: A61K31/4365 ,  A61K9/20 ,  A61K47/08 ,  A61K47/10 ,  A61K47/22 ,  A61K47/26 ,  A61K2121/00

    Abstract: A composition comprising clopidogrel besylate is provided to show high in vitro dissolution rate and have excellent stability without adding a separate additive such as an antioxidant by preparing the clopidogrel besylate in a solid dispersion with a copolymer of polyoxyethylene and polyoxypropylene and crospovidone as a disintegrant. A pharmaceutical composition comprises a clopidogrel besylate-containing solid dispersion prepared by dispersing 100 parts by weight of clopidogrel besylate, 3-15 parts by weight of a copolymer of polyoxyethylene and polyoxypropylene, 30-60 parts by weight of polyethyleneglycol and 5-20 parts by weight of crospovidone in 55-70 parts by weight of mannitol; and a pharmaceutically acceptable carrier such as a copolymer of polyoxyethylene and polyoxypropylene, crospovidone and a mixture thereof. A method for preparing the composition comprises the steps of: (a) dissolving clopidogrel besylate, a copolymer of polyoxyethylene and polyoxypropylene, polyethyleneglycol and crospovidone in 50-100% ethanol or an aqueous solution of ethanol; (b) dispersing the solution obtained from the step(a) in mannitol and then drying or spraying the solution of the step(a) with fluidizing the mannitol in a granulator to obtain a clopidogrel besylate-containing solid dispersion; and (c) mixing the clopidogrel besylate-containing solid dispersion with a pharmaceutically acceptable carrier. Further, the 0.2-0.4 wt.% of ethanol or an aqueous solution of ethanol is used based on the 100 wt.% of clopidogrel besylate.

    Abstract translation: 提供了包含氯吡格雷苯磺酸盐的组合物，以显示高体外溶出速率并且具有优异的稳定性，而不用添加单独的添加剂如抗氧化剂，通过制备固体分散体中的氯吡格雷苯磺酸盐与聚氧乙烯和聚氧丙烯的共聚物和交聚维酮作为崩解剂。 药物组合物包含通过将100重量份苯磺酸氯吡格雷，3-15重量份的聚氧乙烯和聚氧丙烯的共聚物，30-60重量份的聚乙二醇和5-20重量份的聚乙二醇和 交联聚维酮的重量为55-70重量份的甘露糖醇; 和药学上可接受的载体，例如聚氧乙烯和聚氧丙烯的共聚物，交聚维酮及其混合物。 制备组合物的方法包括以下步骤：（a）将乙酸氯吡格雷，聚氧乙烯和聚氧丙烯的共聚物，聚乙二醇和交聚维酮溶于50-100％乙醇或乙醇水溶液中; （b）将从步骤（a）获得的溶液分散在甘露醇中，然后在制粒机中使甘露醇流化，干燥或喷雾步骤（a）的溶液，得到含氯吡格雷的固体分散体; 和（c）将含氯吡格雷苯磺酸盐的固体分散体与药学上可接受的载体混合。 此外，基于100重量％的氯吡格雷苯磺酸盐，使用0.2-0.4重量％的乙醇或乙醇水溶液。

    나노에멀젼 형태의 안과용 조성물
    36.
    发明授权
    나노에멀젼 형태의 안과용 조성물 有权
    纳米乳液形式的光学组成

    公开(公告)号：KR101151235B1

    公开(公告)日：2012-06-14

    申请号：KR1020110113084

    申请日：2011-11-02

    Applicant: 한림제약(주)

    Inventor： 이성일 ,  양재식 ,  이근혁 ,  최병선 ,  류종현

    IPC: A61K47/30 ,  A61K38/13 ,  A61K47/44 ,  A61P27/02

    CPC classification number: A61K38/13 ,  A61K47/30 ,  A61K47/44 ,  Y10S514/912

    Abstract: PURPOSE: A composition containing a nanoemulsion form prepared by self-emulsification using cyclosporine A together with special oil and surfactant in aqueous medium is provided to enable sterilizing and to ensure stability. CONSTITUTION: An opthalmic composition of a nanoemulsion form with 200nm or less of particles size contains 0.05 w/v% of cyclosporine A, 0.05 v/v% of propylene glycol dicaprylocaprate, 0.37 v/v% of triglyceride, and 1.15 v/v% of polyoxyl 35 hydrogenate castor oil in an aqueous medium. The composition additionally contains sodium phosphate or hydrate thereof, sodium dihydrogenphosphate or hydrate thereof, or mixture thereof.

    Abstract translation: 目的：提供含有通过使用环孢菌素A与特殊油和表面活性剂在水性介质中自乳化而制备的纳米乳液形式的组合物，以便消毒并确保稳定性。 构成：具有200nm或更小颗粒尺寸的纳米乳剂形式的眼组合物含有0.05w / v％的环孢菌素A，0.05v / v％的丙二醇二辛酸钠，0.37v / v％的甘油三酸酯和1.15v / v％ 的聚氧乙烯35氢化蓖麻油在水性介质中。 该组合物还含有磷酸钠或其水合物，磷酸二氢钠或其水合物，或其混合物。

    비스포스포네이트 유도체 및 고용량의 콜레칼시페롤을 포함하는 약학 조성물
    38.
    发明公开
    비스포스포네이트 유도체 및 고용량의 콜레칼시페롤을 포함하는 약학 조성물 无效
    包含二磷酸酯衍生物和大量CHOLECALCIFEROL的药物组合物

    公开(公告)号：KR1020110088474A

    公开(公告)日：2011-08-03

    申请号：KR1020110059728

    申请日：2011-06-20

    Applicant: 한림제약(주)

    Inventor： 김진선 ,  이근혁 ,  최병선 ,  김재신 ,  박진하 ,  오미진 ,  김은미

    IPC: A61K31/675 ,  A61K31/59 ,  A61P19/10

    CPC classification number: A61K31/675 ,  A61K9/2866 ,  A61K31/593 ,  A61K31/663

    Abstract: PURPOSE: A pharmaceutical composition containing bisphonate derivatives and high dose of cholecalciferol is provided to prevent or treat osteoporosis. CONSTITUTION: A pharmaceutical composition containing bisphonate derivatives and cholecalciferol suppresses bone absorption without side effects including hypercalcemia. A pharmaceutical composition for preventing or treating osteoporosis contains saccharides of unit dosage form, risedronic acid or salt thereof or ibandronic acid or salt thereof, and 24,000-50,000 IU of cholecalciferol. The unit dosage form is a tablet form.

    Abstract translation: 目的：提供含有双酚衍生物和高剂量胆钙化甾醇的药物组合物，用于预防或治疗骨质疏松症。 构成：含有双酚衍生物和胆钙化甾醇的药物组合物抑制骨吸收而没有副作用，包括高钙血症。 用于预防或治疗骨质疏松症的药物组合物含有单位剂型的糖，利塞膦酸或其盐或伊班膦酸或其盐，以及24,000-50,000IU的胆钙化甾醇。 单位剂型是片剂形式。

    암로디핀 니코티네이트를 포함하는 약제학적 조성물
    39.
    发明授权
    암로디핀 니코티네이트를 포함하는 약제학적 조성물 有权

    公开(公告)号：KR101052280B1

    公开(公告)日：2011-07-27

    申请号：KR1020040020768

    申请日：2004-03-26

    Applicant: 한림제약(주)

    Inventor： 김재신 ,  류종현 ,  이근혁 ,  최병선 ,  김진선 ,  하문천

    IPC: A61K31/44 ,  A61K31/455 ,  A61K9/20

    Abstract: 본 발명은 치료학적 유효량의 암로디핀 니코티네이트 또는 (S)-암로디핀 니코티네이트를 포함하고, 붕해제로서 전분 글리콜산 나트륨(sodium starch glycolate) 또는 크로스포비돈(crospovidone)을 포함하는 허혈 또는 고혈압 치료용 약제학적 조성물을 제공한다.
    본 발명의 조성물은 배합변화를 최소화시킬 수 있으며, 우수한 화학적 및 광학적 안정성을 유지할 수 있다. 또한, 본 발명의 조성물은 산성조건하에서 빠른 용출률을 나타내며, 소실반감기가 길게 유지됨으로써 소량의 복용량으로도 약효를 지속적으로 유지할 수 있다.
    암로디핀 니코티네이트

Patent Agency Ranking